By Maxx Chatsko Three privately-held biotech companies could be next in line for making the jump to public markets. Investors enjoyed a record number of biotech IPOs in 2020 and 2021 as companies raced to grab bags of money from public markets flooded with liquidity. The pipeline has dried up considerably in 2022, primarily due to tightening financial conditions. It’s not quite as fun, but it’s a sign of healthy markets. Despite the slowdown, the most promising companies can still drum up enough investor interest to make the numbers work. Prime Medicine (PRME) became one of the largest biotech…